10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bone destruction relies on interactions between bone and immune cells. Bone-resorbing osteoclasts (OCLs) were recently identified as innate immune cells activating T cells toward tolerance or inflammation. Thus, pathological bone destruction not only relies on increased osteoclast differentiation, but also on the presence of inflammatory OCLs (i-OCLs), part of which express Cx3cr1. Here, we investigated the contribution of mouse Cx3cr1 + and Cx3cr1 neg i-OCLs to bone loss. We showed that Cx3cr1 + and Cx3cr1 neg i-OCLs differ considerably in transcriptional and functional aspects. Cx3cr1 neg i-OCLs have a high ability to resorb bone and activate inflammatory CD4 + T cells. Although Cx3cr1 + i-OCLs are associated with inflammation, they resorb less and have in vitro an immune-suppressive effect on Cx3cr1 neg i-OCLs, mediated by PD-L1. Our results provide new insights into i-OCL heterogeneity. They also reveal that different i-OCL subsets may interact to regulate inflammation. This contributes to a better understanding and prevention of inflammatory bone destruction.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.

          We describe the generation of ovalbumin (OVA)-specific, MHC class II-restricted alpha beta T cell receptor (TCR) transgenic mice. Initial attempts at generating these transgenic mice utilized heterologous regulatory elements to drive the expression of cDNA genes encoding the separate alpha- and beta-chains of the TCR. Unexpectedly, T cells bearing the transgenic alpha beta TCR failed to emerge from the thymus in these mice, although the transgenes did modify endogenous TCR expression. However, subsequent modification of the approach which enabled expression of the TCR beta-chain under the control of its natural regulatory elements generated mice whose peripheral T cells expressed the transgenic TCR and were capable of antigen-dependent proliferation. These results show that successful generation of MHC class II-restricted, OVA-specific alpha beta TCR transgenic mice was dependent upon combining cDNA- and genomic DNA-based constructs for expression of the respective alpha- and beta-chains of the TCR.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The origin and development of nonlymphoid tissue CD103+ DCs

            CD103+ dendritic cells (DCs) in nonlymphoid tissues are specialized in the cross-presentation of cell-associated antigens. However, little is known about the mechanisms that regulate the development of these cells. We show that two populations of CD11c+MHCII+ cells separated on the basis of CD103 and CD11b expression coexist in most nonlymphoid tissues with the exception of the lamina propria. CD103+ DCs are related to lymphoid organ CD8+ DCs in that they are derived exclusively from pre-DCs under the control of fms-like tyrosine kinase 3 (Flt3) ligand, inhibitor of DNA protein 2 (Id2), and IFN regulatory protein 8 (IRF8). In contrast, lamina propria CD103+ DCs express CD11b and develop independently of Id2 and IRF8. The other population of CD11c+MHCII+ cells in tissues, which is CD103−CD11b+, is heterogenous and depends on both Flt3 and MCSF-R. Our results reveal that nonlymphoid tissue CD103+ DCs and lymphoid organ CD8+ DCs derive from the same precursor and follow a related differentiation program.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Estrogen deficiency and bone loss: an inflammatory tale.

              Estrogen plays a fundamental role in skeletal growth and bone homeostasis in both men and women. Although remarkable progress has been made in our understanding of how estrogen deficiency causes bone loss, the mechanisms involved have proven to be complex and multifaceted. Although estrogen is established to have direct effects on bone cells, recent animal studies have identified additional unexpected regulatory effects of estrogen centered at the level of the adaptive immune response. Furthermore, a potential role for reactive oxygen species has now been identified in both humans and animals. One major challenge is the integration of a multitude of redundant pathways and cytokines, each apparently capable of playing a relevant role, into a comprehensive model of postmenopausal osteoporosis. This Review presents our current understanding of the process of estrogen deficiency-mediated bone destruction and explores some recent findings and hypotheses to explain estrogen action in bone. Due to the inherent difficulties associated with human investigation, many of the lessons learned have been in animal models. Consequently, many of these principles await further validation in humans.
                Bookmark

                Author and article information

                Contributors
                Role: Reviewing Editor
                Role: Senior Editor
                Journal
                eLife
                Elife
                eLife
                eLife
                eLife Sciences Publications, Ltd
                2050-084X
                13 May 2020
                2020
                : 9
                : e54493
                Affiliations
                [1 ]Laboratoire de PhysioMédecine Moléculaire, CNRS NiceFrance
                [2 ]Université Côte d’Azur NiceFrance
                [3 ]Department of Pharmacy, Cardenal Herrera-CEU University ValenciaSpain
                [4 ]Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health BethesdaUnited States
                [5 ]Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation Montigny-Le-BretonneuxFrance
                [6 ]IRMB, Univ Montpellier, INSERM, CHU Montpellier MontpellierFrance
                [7 ]Genetics division, Ambroise Paré Hospital, AP-HP Boulogne-BillancourtFrance
                Columbia University United States
                The University of Hong Kong Hong Kong
                Columbia University United States
                Author information
                http://orcid.org/0000-0002-0075-9880
                https://orcid.org/0000-0002-2621-3907
                Article
                54493
                10.7554/eLife.54493
                7220377
                32400390
                2da6f3fc-a46a-4d13-bc6e-92d2e674b6e5

                This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

                History
                : 16 December 2019
                : 26 April 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001665, Agence Nationale de la Recherche;
                Award ID: ANR-16-CE14-0030
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001665, Agence Nationale de la Recherche;
                Award ID: ANR-15-IDEX-01
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100002915, Fondation pour la Recherche Médicale;
                Award ID: ECO20160736019
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100008319, Fondation Arthritis;
                Award Recipient :
                Funded by: Société Française de Biologie des TissusMinéralisés;
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100013541, European Calcified Tissue Society;
                Award Recipient :
                Funded by: American Society of Bone and Mineral Research;
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000054, National Cancer Institute;
                Award ID: Intramural Research Program
                Award Recipient :
                The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
                Categories
                Research Article
                Cell Biology
                Immunology and Inflammation
                Custom metadata
                Osteoclasts emerging in inflammation are heterogeneous and encompass a strongly inflammatory subset with a high resorbing activity and an immune suppressive subset that are able to control each other.

                Life sciences
                osteoclast,osteoporosis,osteoimmunology,bone destruction,inflammation,mouse
                Life sciences
                osteoclast, osteoporosis, osteoimmunology, bone destruction, inflammation, mouse

                Comments

                Comment on this article